Evelyn Warner, Author at Labiotech.eu

About

Ex-Editor. Recovering organic chemist. Chagrined member of the Brooklyn-Berlin exchange program. Proud parent of a majestic domestic long hair.

Articles by Evelyn Warner

News and Trends 7 Feb 2018

Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster

TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […]

February 7, 2018 - 1 minutemin - By Evelyn Warner

Interview 7 Feb 2018

Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress

Did you miss us in Vienna? Here’s the first of our two interviews from the Refresh meetup last month: Jörn Aldag, CEO of Hookipa, talked to us about the importance of a sound financial strategy and where cancer vaccines are on the hype curve. Jörn Aldag has had quite a career. His first position as […]

February 7, 2018 - 4 minutesmins - By Evelyn Warner

More News! 6 Feb 2018

Biotech Barometer: How is biotech doing on the European markets?

How did biotech finish last year on Euronext? The exchange has released its report for H2 of 2017 for the 49 biotechs listed on the markets, including giants Galapagos and Ablynx and CAR-T notables Cellectis and Celyad among others. The bottom line of the biotech barometer? It was a good semester! Stock Performance & Market […]

February 6, 2018 - 3 minutesmins - By Evelyn Warner

lig biowise diagnostics antimicrobial resistance

More News! 5 Feb 2018

A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance

A new molecular diagnostics company, LIG Biowise, has just closed a £1.8M Series A fundraising round in its effort to combat antimicrobial resistance. Based in Manchester, LIG Biowise, is working on a DNA-based diagnostic to catch antibiotic resistant infections early. The company has now closed a Series A of £1.8M (€2.0M), led by Hong Kong-based Phoenix Bridge, to fund […]

February 5, 2018 - 1 minutemin - By Evelyn Warner

Interview 29 Jan 2018

Meet the CEO of the Other Big Biotech Acquisition Target in 2017

Christian Schetter’s company, Rigontec, was acquired by MSD last year for nearly half a billion euro. How did he and the company do it, with only one early-stage candidate? There were exactly two notable biotech acquisitions in Europe last year: Actelion and a smaller startup based in Munich called Rigontec, which had an RNA candidate […]

January 29, 2018 - 9 minutesmins - By Evelyn Warner

News and Trends 26 Jan 2018

New British Spinout May Get Snapped Up by Allergan for $400M

KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […]

January 26, 2018 - 1 minutemin - By Evelyn Warner

News and Trends 25 Jan 2018

Novartis Will Bring US Gene Therapy for Blindness to Europe

The Swiss pharma has bought into the gene editing therapy game in a deal with Spark worth $170M (€137M) for commercialization rights outside the US. Novartis first marked out its position as a gene therapy leader in 2012 when it threw its hat into the CAR-T ring. Just a few months after the FDA approved […]

January 25, 2018 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Jan 2018

Another Huge Acquisition Sees CAR-T Stocks Jump – Except for Celyad

Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire Juno: Cellectis rides the wave but Celyad misses it. Shortly after the mega-acquisition of Kite by Gilead, the second prettiest girl at the CAR-T party, Juno Therapeutics, has accepted the advances of Celgene in a $9Bn (€7.4Bn) acquisition. This represents a bullish […]

January 23, 2018 - 2 minutesmins - By Evelyn Warner

Interview 22 Jan 2018

Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target

I sat down with Eduardo Bravo, CEO of TiGenix, to talk about the technology that made his company so attractive to the pharma giant. After beginning his career in big pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called […]

January 22, 2018 - 6 minutesmins - By Evelyn Warner

News and Trends 18 Jan 2018

Report from JP Morgan 2018: Taking the Financial Temperature of Biotech

As heard at JP Morgan 2018, last year was an ok year for biotech. But how does 2018 look? Here are the thoughts of a panel convened to discuss the numbers. A biotech whirlwind swept through San Francisco last week as the industry descended on Union Square for the JP Morgan Healthcare Conference of 2018. […]

January 18, 2018 - 5 minutesmins - By Evelyn Warner

Best in Biotech 9 Jan 2018

Happy 2018, Here Are the Top 9 European Biotech Companies To Watch

As the 2017 reports roll in, we’re already turning our gaze to 2018. These are the top European biotech companies to watch in the new year. The results from last year are rolling in, and it seems to be a mixed bag. Generalist investors are backing away from biotech, but the FDA approved a record […]

January 9, 2018 - 5 minutesmins - By Evelyn Warner

alzheimers disease acimmune andrea pfeifer 1

Interview 8 Jan 2018

Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease

Efforts to treat Alzheimer’s Disease have been hit with failure after failure in the last year or so. Andrea Pfeifer, co-founder and CEO of AC Immune, told me about how her company hopes to pull off a win. Andrea Pfeifer started out as toxicologist in oncology before she moved into entrepreneurship. She left Germany after […]

January 8, 2018 - 8 minutesmins - By Evelyn Warner

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us